Detailed Information on Publication Record
2020
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
MACHOVA POLAKOVA, Katerina, Hana ZIZKOVA, Jan ZUNA, Eliska MOTLOVA, Lenka HOVORKOVA et. al.Basic information
Original name
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
Authors
MACHOVA POLAKOVA, Katerina (203 Czech Republic, guarantor), Hana ZIZKOVA (203 Czech Republic), Jan ZUNA (203 Czech Republic), Eliska MOTLOVA (203 Czech Republic), Lenka HOVORKOVA (203 Czech Republic), Andrea GOTTSCHALK (276 Germany), Ingmar GLAUCHE (276 Germany), Jitka KOBLIHOVA (203 Czech Republic), Pavla PECHERKOVA (203 Czech Republic), Hana KLAMOVA (203 Czech Republic), Marketa STASTNA MARKOVA (203 Czech Republic), Dana SRBOVA (203 Czech Republic), Adela BENESOVA (203 Czech Republic), Vaclava POLIVKOVA (203 Czech Republic), Tomáš JURČEK (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Thomas ERNST (276 Germany), Francois X. MAHON (250 France), Susanne SAUSSELE (276 Germany), Ingo ROEDERVIEW (276 Germany), Nicholas C. P. CROSS (826 United Kingdom of Great Britain and Northern Ireland) and Andreas HOCHHAUS (276 Germany)
Edition
Leukemia, London, Nature Publishing Group, 2020, 0887-6924
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 11.528
RIV identification code
RIV/00216224:14110/20:00116511
Organization unit
Faculty of Medicine
UT WoS
000632227000002
Keywords in English
chronic myeloid leukaemia; genomic PCR
Tags
International impact, Reviewed
Změněno: 8/4/2021 07:46, Mgr. Tereza Miškechová
Abstract
V originále
This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n=17) or scheduled interruption (n=25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS=57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS=20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.
Links
LM2018128, research and development project |
|